开拓创新、协同攻关，助力人血白蛋白的迭代研发及临床研究

贾继东; 牛俊奇

doi:10.12449/JCH250301

开拓创新、协同攻关，助力人血白蛋白的迭代研发及临床研究

DOI: 10.12449/JCH250301

贾继东^1, , ,,
牛俊奇²

1.
首都医科大学附属北京友谊医院肝病中心，北京 100050
2.
吉林大学第一医院肝胆胰内科，传染病与病原生物学中心，长春 130021

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：贾继东负责拟定选题，撰写稿件；牛俊奇负责审定终稿。

详细信息

通信作者:
贾继东， jia_jd@ccmu.edu.con （ORCID： 0000-0002-4673-8890）

计量
- 文章访问数: 1853
- HTML全文浏览量: 93
- PDF下载量: 58
- 被引次数: 0
出版历程
- 收稿日期: 2025-02-26
- 录用日期: 2025-03-10
- 出版日期: 2025-03-25

Driving innovation and fostering collaboration to advance the development and clinical research of next-generation human serum albumin

Jidong JIA^{1
, ,
,},
Junqi NIU²

1.
Liver Research Center，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China
2.
Department of Hepatology，The First Hospital of Jilin University，Center of Infectious Diseases and Pathogen Biology，Changchun 130021，China

More Information

Corresponding author: JIA Jidong， jia_jd@ccmu.edu.cn （ORCID： 0000-0002-4673-8890）

摘要

摘要: 白蛋白是人血浆中含量最高的蛋白质，除维持血浆胶体渗透压外，还有物质转运、解毒、维持血管完整性、抗氧化、抗炎及免疫调控等功能。在肝病领域，目前白蛋白主要用于预防大量放腹水后循环功能障碍和治疗肝硬化低白蛋白血症和腹水、自发性腹膜炎以及肝肾综合征。研发重组人血白蛋白有助于降低人血白蛋白制品的潜在生物安全风险和大量依赖进口的弊端。由于缺乏对已上市人血白蛋白关键注册临床试验结果的借鉴，人血白蛋白的临床试验设计、实施和审评均面临诸多挑战。因此需要制药企业、临床医学、方法学以及评审监管等方面的专家，求真务实、锐意创新、协同攻关。
- 白蛋白类 /
- 重组人血白蛋白 /
- 肝硬化 /
- 临床试验
Abstract: Albumin is the most abundant protein in human plasma， and in addition to the function of maintaining plasma colloid osmotic pressure， it also has the functions of material transport， detoxification， maintaining vascular integrity， antioxidation， anti-inflammation， and immune modulation. In the field of liver disease， albumin is mainly used to prevent circulatory dysfunction after large-volume paracentesis and treat cirrhotic hypoalbuminemia and ascites， spontaneous bacterial peritonitis， and hepatorenal syndrome. The development of recombinant human serum albumin helps to reduce the potential biosafety risks of human serum albumin products and the disadvantages of relying heavily on import. Due to the lack of reference to the results of pivotal clinical trials of marketed human albumin products， there are still various challenges in the design， implementation， and evaluation of clinical trials of human albumin. Therefore， experts in pharmaceutical enterprises， clinical medicine， methodology， and evaluation/supervision are needed to be pragmatic， innovative and collaborative.
- Albumins /
- Recombinant Human Serum Albumin /
- Liver Cirrhosis /
- Clinical Trial

HTML全文

参考文献(20)

[1]	CARACENI P, O’BRIEN A, GINES P. Long-term albumin treatment in patients with cirrhosis and ascites[J]. J Hepatol, 2022, 76( 6): 1306- 1317. DOI: 10.1016/j.jhep.2022.03.005.
[2]	MURPHY G, BRAYDEN DJ, CHEUNG DL, et al. Albumin-based delivery systems: Recent advances, challenges, and opportunities[J]. J Control Release, 2025, 380: 375- 395. DOI: 10.1016/j.jconrel.2025.01.035.
[3]	FEATHERSTONE PJ, BALL CM. The development of albumin solutions in the second world war[J]. Anaesth Intensive Care, 2023, 51( 4): 236- 238. DOI: 10.1177/0310057X231174704.
[4]	FEATHERSTONE PJ, BALL CM. From conflict to controversy: The use and abuse of human albumin solutions after the Second World War[J]. Anaesth Intensive Care, 2023, 51( 6): 368- 371. DOI: 10.1177/0310057X231199368.
[5]	SANER FH, STUEBEN BO, HOYER DP, et al. Use or misuse of albumin in critical ill patients[J]. Diseases, 2023, 11( 2): 68. DOI: 10.3390/diseases11020068.
[6]	WIEDERMANN CJ, ZABOLI A, TURCATO G. Synthesis of expert opinions on fluid management in severe sepsis: A contextual review of human albumin and crystalloids[J]. Heart Lung, 2025, 70: 339- 359. DOI: 10.1016/j.hrtlng.2025.01.010.
[7]	GARCIA-TSAO G, ABRALDES JG, RICH NE, et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review[J]. Gastroenterology, 2024, 166( 1): 202- 210. DOI: 10.1053/j.gastro.2023.10.016.
[8]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
[9]	CHINA L, FREEMANTLE N, FORREST E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis[J]. N Engl J Med, 2021, 384( 9): 808- 817. DOI: 10.1056/NEJMoa2022166.
[10]	SOLÀ E, SOLÉ C, SIMÓN-TALERO M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial[J]. J Hepatol, 2018, 69( 6): 1250- 1259. DOI: 10.1016/j.jhep.2018.08.006.
[11]	CHRIS RUNKEN M, CARACENI P, FERNANDEZ J, et al. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain[J]. Health Econ Rev, 2019, 9( 1): 22. DOI: 10.1186/s13561-019-0237-7.
[12]	HASAN I, MURTI IS, BAYUPURNAMA P, et al. Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings[J]. Drugs Context, 2024, 13: 2024-2021- 1. DOI: 10.7573/dic.2024-1-1.
[13]	BALDASSARRE M, NALDI M, ZACCHERINI G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications[J]. Hepatology, 2021, 74( 4): 2058- 2073. DOI: 10.1002/hep.31798.
[14]	ERSTAD BL. Introduction to the concept of effective albumin concentration[J]. Am J Health Syst Pharm, 2024, 82( 1): 5- 11. DOI: 10.1093/ajhp/zxae232.
[15]	CHEN Z, HE Y, SHI B, et al. Human serum albumin from recombinant DNA technology: Challenges and strategies[J]. Biochim Biophys Acta, 2013, 1830( 12): 5515- 5525. DOI: 10.1016/j.bbagen.2013.04.037.
[16]	ABRALDES JG, TREBICKA J, CHALASANI N, et al. Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension[J]. Hepatology, 2019, 69( 3): 1287- 1299. DOI: 10.1002/hep.30314.
[17]	TORP N, ISRAELSEN M, COENRAAD M, et al. Personalised human albumin in patients with cirrhosis and ascites: Design and rationale for the ALB-TRIAL- a randomised clinical biomarker validation trial[J]. BMJ Open, 2024, 14( 2): e079309. DOI: 10.1136/bmjopen-2023-079309.
[18]	GENTILINI P, CASINI-RAGGI V, DI FIORE G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial[J]. J Hepatol, 1999, 30( 4): 639- 645. DOI: 10.1016/s0168-8278(99)80194-9.
[19]	CARACENI P, ANGELI P, PRATI D, et al. AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: A 2020 update[J]. Blood Transfus, 2021, 19( 1): 9- 13. DOI: 10.2450/2020.0414-20.
[20]	KALO E, READ S, BAIG A, et al. Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia[J]. JGH Open, 2024, 8( 9): e70029. DOI: 10.1002/jgh3.70029.